A5033906229- Cystic Fibrosis Research Advances
- Neonatal Respiratory Health Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Pneumonia and Respiratory Infections
- Tracheal and airway disorders
- Pediatric health and respiratory diseases
- Respiratory viral infections research
- Respiratory Support and Mechanisms
- Respiratory and Cough-Related Research
- COVID-19 Clinical Research Studies
- Asthma and respiratory diseases
- Nosocomial Infections in ICU
- Long-Term Effects of COVID-19
- Sepsis Diagnosis and Treatment
- Advanced Chemical Sensor Technologies
- Pneumocystis jirovecii pneumonia detection and treatment
- Intensive Care Unit Cognitive Disorders
- Antibiotic Resistance in Bacteria
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Inhalation and Respiratory Drug Delivery
- SARS-CoV-2 and COVID-19 Research
- Congenital Diaphragmatic Hernia Studies
- Childhood Cancer Survivors' Quality of Life
- Emergency and Acute Care Studies
- Dysphagia Assessment and Management
Universitat de Barcelona
2003-2025
Hospital Clínic de Barcelona
2006-2025
Hospital de Sant Pau
2016-2025
Museo Nacional de Sanidad
2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2003-2024
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
2008-2024
Biomedical Research Institute
2016-2024
Instituto de Salud Carlos III
2021-2024
Canadian Respiratory Research Network
2023
Centro de Investigación Biomédica en Red
2022
IMPORTANCEIn patients with severe community-acquired pneumonia, treatment failure is associated excessive inflammatory response and worse outcomes.Corticosteroids may modulate cytokine release in these patients, but the benefit of this adjunctive therapy remains controversial.OBJECTIVE To assess effect corticosteroids communityacquired pneumonia high response.DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized, double-blind, placebo-controlled trial conducted 3 Spanish teaching...
Rationale: Sputum neutrophil elastase and serum desmosine, which is a linked marker of endogenous elastin degradation, are possible biomarkers disease severity progression in bronchiectasis. This study aimed to determine the association activity desmosine with exacerbations lung function decline bronchiectasis.Methods: was single-center prospective cohort using TAYBRIDGE (Tayside Bronchiectasis Registry Integrating Datasets, Genomics, Enrolment into Clinical Trials) registry Dundee, UK. A...
BackgroundNeutrophil extracellular traps (NETs) have been observed in the airway patients with chronic obstructive pulmonary disease (COPD), but their clinical and pathophysiologic implications not defined.ObjectiveWe sought to determine whether NETs are associated severity COPD how they microbiota composition neutrophil function.MethodsNET protein complexes (DNA-elastase histone-elastase complexes), cell-free DNA, biomarkers were quantified soluble sputum serum from during periods of...
Patients with bronchiectasis have frequent exacerbations that are thought to be related neutrophilic inflammation. The activity and quantity of neutrophil serine proteases, including elastase, increased in the sputum patients at baseline increase further during exacerbations. Brensocatib (INS1007) is an oral reversible inhibitor dipeptidyl peptidase 1 (DPP-1), enzyme responsible for activation proteases.In a phase 2, randomized, double-blind, placebo-controlled trial, we randomly assigned,...
Pseudomonas aeruginosa is a challenging bacterium to treat due its intrinsic resistance the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about global burden and risk factors associated P. -CAP are limited. We assessed multinational specific aeruginosa- CAP. enrolled 3193 54 countries confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according identification . Logistic regression analysis...
Rationale: Bronchiectasis is classically considered a neutrophilic disorder, but eosinophilic subtypes have recently been described. Objectives: To use multiple datasets available through the European Multicentre Audit and Research Collaboration to characterize bronchiectasis as clinical entity focusing on impact of eosinophils exacerbations. Methods: Patients were included from five countries examine relationships between blood eosinophil counts phenotypes after excluding coexisting asthma....
COPD and bronchiectasis are commonly reported together. Studies report varying impacts of co-diagnosis on outcomes, which may be related to different definitions disease used across studies.
Background International guidelines recommend airway clearance management as one of the important pillars bronchiectasis treatment. However, extent to which is used for people with in Europe unclear. The aim study was identify use patients across different countries and factors influencing use. Methods This a prospective observational using data from European Multicentre Bronchiectasis Audit Research Collaboration (EMBARC) Registry between January 2015 April 2022. Prespecified options were...
Rationale: Up to one-third of patients hospitalized with pneumococcal pneumonia experience major adverse cardiac events (MACE) during or after pneumonia. In mice, Streptococcus pneumoniae can invade the myocardium, induce cardiomyocyte death, and disrupt function following bacteremia, but it is unknown whether same occurs in humans severe pneumonia.Objectives: We sought determine S. (1) translocate heart, (2) (3) cause MACE, (4) scar formation antibiotic treatment using a nonhuman primate...
The diagnostic label "bronchiectasis" describes the existence of localised and permanent airway dilation, but when used to describe a disease it includes heterogeneous group disorders that differ significantly in terms aetiological, clinical, radiological, functional microbial features \[1]. Using cluster analysis, some previous studies have attempted identify distinct "clinical phenotypes" patients with bronchiectasis [2–4\] (defined as "a single or combination attributes differences...
Rationale: The principal underlying inhaled antibiotic treatment in bronchiectasis is that airway bacterial load drives inflammation, and therefore will reduce symptoms. Objectives: To determine the relationship between clinical outcomes, assess stability of over time, test hypothesis response to antibiotics would be predicted by baseline load. Methods: We performed three studies. Studies 1 2 were prospective studies including adults with bronchiectasis. Study 3 was a post hoc analysis...
Some COVID-19 survivors present lung function abnormalities during follow-up, particularly reduced carbon monoxide diffusing capacity (DLCO). To investigate risk factors and underlying pathophysiology, we compared the clinical characteristics levels of circulating pulmonary epithelial endothelial markers in with normal or DLCO 6 months after discharge.
Rationale: Although inflammation and infection are key disease drivers in bronchiectasis, few studies have integrated host inflammatory microbiome data to guide precision medicine. Objectives: To identify clusters among patients with bronchiectasis on the basis of markers assess association between endotypes, characteristics, exacerbation risk. Methods: Patients stable were enrolled at three European centers, cluster analysis was used stratify according levels 33 sputum serum markers....
C-reactive protein (CRP), an active regulator of the innate immune system, has been related to COVID-19 severity. CRP is a dynamic undergoing conformational changes upon activation in inflammatory microenvironments between pentameric and monomeric isoforms. Although circulating isoform routinely tested for clinical purposes, shows more proinflammatory properties. Therefore, we aimed determine potential serum as biomarker disease severity patients (admission intensive care unit [ICU] and/or...
Asthma is commonly reported in patients with a diagnosis of bronchiectasis.
Background A validated 4-point sputum colour chart can be used to objectively evaluate the levels of airway inflammation in bronchiectasis patients. In European Bronchiectasis Registry (EMBARC), we tested whether would associated with disease severity and clinical outcomes. Methods We a prospective, observational registry adults conducted 31 countries. Patients who did not produce spontaneous were excluded from analysis. The Murray was at baseline follow-up visits. Key outcomes frequency...
Bronchiectasis is characterized by acute exacerbations, but the biological mechanisms underlying these events are poorly characterized.
Introduction The Spanish Society of Pulmonology and Thoracic Surgery created a registry for hospitalised patients with COVID-19 the different types respiratory support used (RECOVID). Objectives. To describe profile COVID-19, comorbidities, treatments setting. In addition, we aimed to identify varying profiles according outcomes complexity needed.